Phase 3 N=61 Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
Urge Urinary Incontinence
Primary: Percentage With Treatment Success — 74.1; 75.0 percentage of participants — p=1.0
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 A Study of LY2216684 and Digoxin in Healthy Subjects
Major Depressive Disorder
Primary: Pharmacokinetics of Digoxin: Maximum Plasma Concentration (Cmax) — 1.433; 1.424 nanograms/milliliter (ng/mL)
Phase 1 N=47 A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
Major Depressive Disorder
Primary: Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) — 61.8; 55.3 hours*nanograms/milliliters (h*ng/mL)
Phase 1 N=36 A Study of LY2216684 in Participants With Impaired Hepatic Function
Depressive Disorder, Major
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) — 601; 742; 961; 1020 hours times nanograms/milliliter
N/A N=501 Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure
Heart Failure, Congestive
Primary: Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion. — 58 hospitalization
N/A N=46 the Effect of Dopamine on Mechanical Ventilation Induced Lung Injury
Acute Lung Injury
Primary: Correlation Coefficient (r) Between Duration of Mechanical Ventilation and DRD1 Expression — -0.555 pearson Correlation Coefficient — p=<0.01
N/A N=674 A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
Hypertension
Primary: Percentage of Subjects With Adverse Events — 3.28; 3.80 percentage of participants
Phase 1 N=20 A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
Major Depressive Disorder
Primary: Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684 — 677; 1210 hour*nanogram per…
N/A N=14 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Diastolic Heart Failure · Hypertensive Heart Disease
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17
N/A N=49 Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Pseudophakia · Inflammation
Primary: Investigate Clinical Outcomes for Intraocular Pressure After Treatment With Lotemax (Loteprednol Ophthalmic Solution) 0.5% QID in Subjects Who Have Undergone Cataract…
Phase 3 N=457 A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -17.9; -17.3; -13.1 units on a scale — p=0.050
Phase 4 N=50 Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COPD · Chronic Bronchitis · Emphysema
Primary: The Primary Outcome Measure is the Rate of Exacerbations as Defined Using the Winnipeg Criteria. — 5.5; 4 exacerbations per 12 weeks
Phase 1 N=75 A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
Healthy
Primary: Drug Liking: Peak Effect (Emax) — 51.6; 70.1; 85.5; 59.3 mm — p=<0.0001
N/A N=103 Comparison Between the I-gel and the LMA-Unique
Anaesthesia
Primary: Oropharyngeal Leak Pressure — 25.06; 28.24; 22.88; 26.62 cm H20
N/A N=90 Anger Self-Management in Traumatic Brain Injury
Traumatic Brain Injury
Primary: Post-Treatment Response Rate From Baseline on Anger Measures - Participant Report — 46.7; 68.3; 21.7; 50.0 percentage of participants — p=0.047